NasdaqGS:LENZPharmaceuticals
Does LENZ Therapeutics' (LENZ) VIZZ Middle East Deal Reframe Its Global Ophthalmology Ambitions?
LENZ Therapeutics and Lunatus Marketing & Consulting FZCO recently announced an exclusive agreement for Lunatus to register and commercialize VIZZ, an FDA-approved aceclidine-based eye drop for presbyopia, across multiple Middle East markets including the UAE, Saudi Arabia and Qatar.
The deal builds on VIZZ’s early U.S. launch, where the product generated about US$1.6 million in Q4 2025 revenue from over 20,000 prescriptions and broad uptake by eye care professionals.
We’ll explore how early...